Pandemic Influenza Plan

Objectives

The 2017 update to the United States Department of Health and Human Services pandemic influenza plan provides a 2017–2027 framework to protect health and community functioning before, during and after a pandemic. It updates the 2005 plan, incorporates lessons from the 2009 H1N1 pandemic and subsequent outbreaks, and recognises that pandemic timing, severity, transmissibility and social and economic consequences are inherently uncertain.[1][2][3]The framework uses an end-to-end systems approach that integrates preparedness and response across sectors and disciplines, while allowing actions to be adapted to the characteristics of a particular pandemic.[4][5]

• Strengthen surveillance, epidemiology and laboratory activities to improve the timeliness, quality, geographic coverage and scientific precision of data on seasonal, animal and novel influenza viruses.[5][6]
• Implement community mitigation measures, including non-pharmaceutical interventions, as an early means of slowing transmission before pandemic vaccines are broadly available.[7][8]
• Develop, manufacture, stockpile, distribute and monitor medical countermeasures, including diagnostics, vaccines, therapeutics, respirators and ventilators.[9][10]
• Prepare health and care systems to provide appropriate care at the appropriate time and place, sustain essential services, protect the workforce, manage surge demand and support behavioural health.[11][12]
• Improve public communications and outreach through accurate, timely, accessible and audience-tailored information, supported by tested plain-language messaging and multiple communication channels.[4][13][14]
• Build scientific infrastructure that can identify research needs, generate and share time-sensitive evidence, assess interventions and improve current and future responses.[15][16]
• Enhance domestic and international response policy, incident management, global partnerships and capacity building, recognising that pandemic threats can emerge anywhere and cross jurisdictions.[17][18]

Key outcome ambitions include making initial pandemic vaccine doses available within approximately 12 weeks or three months of a pandemic declaration or emergence of a pandemic strain, compared with conventional seasonal production timelines of six to nine months.[19][20]The plan also seeks broader and longer-lasting influenza vaccines, broad-spectrum and paediatric therapeutics, rapid point-of-care and home diagnostics, and respiratory protection that is both effective and practical for users.[21][22]

Implementation

Implementation combines continual preparedness activities with flexible, evidence-led escalation during an outbreak. The Department of Health and Human Services leads the civilian federal role and coordinates with other federal agencies, state, local, tribal and territorial authorities, health-care and public-health organisations, laboratories, manufacturers, businesses, academia, nongovernmental organisations, international partners and the public.[23][5][18]Pandemic planning is linked to seasonal influenza systems and to wider infectious-disease preparedness, so that routine surveillance, laboratories, clinical networks and response capabilities can provide a platform for emerging threats.[24][25]

• Use the Pandemic Intervals Framework to organise actions across investigation, recognition, initiation, acceleration, deceleration and preparation intervals, while allowing jurisdictions to act at different times according to local epidemiology.[26][27]
• Apply the Influenza Risk Assessment Tool to assess the likelihood of sustained human-to-human transmission and potential public-health impact of novel influenza A viruses, informing diagnostic, vaccine, therapeutic and stockpiling decisions.[26][28]
• Assess transmissibility and clinical severity through the Pandemic Severity Assessment Framework, updating initial assessments as surveillance, investigations and case data improve.[29][30]
• Expand global and domestic surveillance, laboratory capacity, genomic sequencing, electronic reporting, diagnostic-reagent distribution and data sharing to detect, characterise and track viruses, antiviral resistance and vaccine effectiveness.[6][31]
• Deploy graded community measures in schools, workplaces, households, travel settings and other community venues, supported by culturally appropriate materials and assessment of likely social and economic effects.[7][8]
• Coordinate the Public Health Emergency Medical Countermeasures Enterprise across research, development, regulation, procurement, stockpiling, distribution, dispensing, administration and performance assessment.[21]
• Use health-care coalitions, interoperable communications, resource-sharing agreements, telehealth, home-based care, emergency standards and volunteer mechanisms to sustain care during surges.[32][13][33]
• Coordinate incident management through the National Incident Management System, National Response Framework and Biological Incident Annex, with the HHS Disaster Leadership Group supporting department-wide policy coordination.[18]

International delivery includes collaboration with the World Health Organization Global Influenza Surveillance and Response System, implementation of the Pandemic Influenza Preparedness Framework and International Health Regulations, and capacity-building partnerships with countries at risk of pandemic emergence.[23][34][25]Operational readiness also depends on resolving staffing, procurement, contracting, grants-management, hiring, supply-chain and statutory-authority constraints that may impede emergency action.[5][33]

Monitoring centres on year-round surveillance, laboratory characterisation, vaccine and antiviral safety and effectiveness, health-system situational awareness, research, exercises and reviews.[31][11][34]The plan identifies interval indicators, risk assessments, communication testing, clinical studies and annual Public Health Emergency Medical Countermeasures Enterprise planning as accountability-supporting mechanisms, but the supplied material does not specify a consolidated performance-indicator framework, reporting timetable or comprehensive evaluation governance.[26][21][14]

Resource needs include sustained investment in vaccine manufacturing and stockpiles, surveillance and laboratory systems, research networks, health-care resilience, communications and international capacity.[20][15]The material does not provide a consolidated programme budget or allocations by domain, although it estimates that a moderate unmitigated pandemic could generate direct and indirect health costs approaching 181 billion US dollars, excluding trade and other business disruption.[3]

Monitoring & Evaluation

Monitoring and evaluation centre on continuous domestic and international influenza surveillance, laboratory characterisation, epidemiological analysis, risk assessment, scientific research and response exercises. These mechanisms are intended to detect novel influenza viruses rapidly, assess pandemic severity and countermeasure performance, guide interventions, and incorporate lessons into future preparedness.[26][5][34]

• Maintain year-round surveillance of seasonal, zoonotic, novel and animal influenza viruses through public-health partners, laboratories, health-care providers, clinics, emergency departments and international networks.[5][6]
• Improve the timeliness, geographic reach, interoperability and precision of surveillance through sequencing, laboratory reporting, electronic health records, social media, large data repositories, geographic information systems and forecasting models.[6][31]
• Use automated electronic laboratory reporting to provide real-time standardised messages from United States public-health laboratories; the system reports about 80,000 influenza tests annually.[31]
• Apply the Pandemic Intervals Framework, which identifies investigation, recognition, initiation, acceleration, deceleration and preparation intervals, alongside associated indicators and interventions.[26]
• Apply the Influenza Risk Assessment Tool to assess the likelihood that novel influenza A viruses will achieve sustained human-to-human transmission and cause significant public-health impact, with reassessment as new evidence emerges.[26][28]
• Assess transmissibility and clinical severity through the Pandemic Severity Assessment Framework, using an initial assessment when evidence is limited and increasingly refined scales as reliable data become available.[28][30]
• Monitor influenza vaccine effectiveness and safety through the United States Flu Vaccine Effectiveness Network, including mid-season and post-season estimates and selected age-specific and product-specific measures.[31]
• Track the safety, effectiveness, demand, distribution, dispensing and administration of medical countermeasures, including vaccines, therapeutics and respiratory devices.[9][10]
• Evaluate vaccines and therapeutics through clinical studies, including phase 3 field-efficacy trials for vaccine candidates and studies supporting product approval or emergency use.[11][16]
• Assess the effectiveness, timing, acceptability and communication of non-pharmaceutical interventions, including individual and combined measures, school and childcare closures, and travel or border health actions.[8]
• Use health-care system status reporting and interoperable communications to develop a common operating picture of capacity, capability and operational stress.[12]
• Conduct preparedness reviews, exercises and improvement processes, including state, local, tribal and territorial planning, annual communications exercises, and a 2015 tabletop exercise on accountable emergency-fund management.[2][14][33]
• Require state-level recipients of public-health emergency preparedness and response funds to establish efficient local allocation procedures and reporting and monitoring methods for accountability.[33]

The source provides selected operational measures and progress examples, including more than 28,000 health-care coalition members, almost 50,000 Medical Reserve Corps volunteers available during the 2009 A(H1N1) response, and 41 notifications to the World Health Organization concerning novel influenza events since 2005.[32][13][34]It does not specify a consolidated document-wide indicator framework, performance targets, reporting timetable, evaluation methodology or single formal accountability body.[4][18][3]

Costing & Financing

Preparedness is presented as requiring sustained investment in surveillance, laboratory systems, scientific infrastructure, vaccine manufacturing, stockpiles, medical-countermeasure development, health-system readiness, communications and international capacity building. Budget priorities and fiscal capability are recognised as factors shaping implementation, but the source does not provide a consolidated programme budget or costed implementation plan.[4][21][25]

• Maintain domestic vaccine-manufacturing capacity, pre-pandemic vaccine and adjuvant stockpiles, antiviral stockpiles, diagnostic capacity, respiratory devices and other medical countermeasures.[1][9][22]
• Allocate resources through the Public Health Emergency Medical Countermeasures Enterprise annual strategy and implementation plan, which is intended to align priorities with scientific progress and fiscal capabilities.[21]
• Improve funding, procurement, contracting, grants management and hiring processes, including emergency administrative and fiscal procedures in state and local response plans.[33]
• Support global surveillance, laboratory systems, sequencing, vaccine-effectiveness monitoring, research networks and response capacity, particularly in resource-limited countries.[6][31][25]
• Use funding and reimbursement opportunities, equipment-sharing arrangements, volunteers and existing communication infrastructure to support health-care preparedness and resource mobilisation.[32][13]

Financial information is limited. The source identifies competing demands for limited resources and the need to optimise public-health and scientific-infrastructure investments, but does not specify allocations by domain, funding sources, financing commitments, quantified funding gaps or resource-mobilisation targets.[5][25]

Available economic evidence indicates that past influenza pandemics caused losses described as hundreds of billions of United States dollars.[19]A moderate unmitigated pandemic is estimated to generate direct and indirect health costs approaching 181 billion United States dollars, excluding trade disruption and other business and industry costs.[3]The 2014-2015 United States highly pathogenic avian influenza response cost federal taxpayers more than 950 million United States dollars.[35]